Preparation method and application of GSH (glutathione) and PH (potential of hydrogen) dual-response chemotherapy and photo-thermal combined therapy drug delivery carrier
A delivery carrier and combination therapy technology, applied in the interdisciplinary fields of chemistry, materials and biology, can solve the problems of high toxicity and side effects of chemotherapy, low curative effect, uncontrollable drug delivery, etc., and achieve significant economic and social benefits, simple method and responsiveness Significant effect with combined effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0045] A method for preparing a GSH and PH dual-response drug delivery carrier for combined chemotherapy and photothermal therapy, comprising the following steps:
[0046] (1) Amino-modified degradable dendritic mesoporous silicon DDMSNs-NH 2 Preparation of:
[0047] Using the surfactant CTAB as the structure-directing agent, TEOS and BTES as the silicon source, and TEA as the catalyst, DDMSNs were synthesized by a one-pot method. Add 0.034 g of TEA and 12.5 mL of deionized water into a 100 mL round-bottom flask, and uniformly magnetically stir in an oil bath at 80 °C for 0.5 h. Then 0.19 g CTAB and 0.042 g NaSal were added, and stirring was continued for 1 h. After CTAB and NaSal were completely dissolved, a mixed solution of 1 mL TEOS and 0.8 mL BTES was added dropwise, and stirring was continued for 12 h. After the reaction, the product was recovered by centrifugation at 20,000 rpm for 10 min and washed with ethanol three times. Finally, the light yellow powder was dried...
Embodiment 2
[0055] A method for preparing a GSH and PH dual-response drug delivery carrier for combined chemotherapy and photothermal therapy, comprising the following steps:
[0056] (1) Amino-modified degradable dendritic mesoporous silicon DDMSNs-NH 2 The preparation is with embodiment 1.
[0057] (2) Drug loading:
[0058] 50 mg DDMSNs-NH 2 Disperse in 50 mL 0.3 mg mL -1 DOX solution (water:PBS = 1:9), stirred at room temperature for 12 h in the dark. After drug loading, centrifuge at 20,000 rpm for 10 min, and collect the supernatant. Then wash with PBS until the supernatant is nearly colorless. All the supernatants were collected, and the DOX content in the supernatant solution was measured at 488 nm with a UV-Vis spectrophotometer to calculate the drug loading.
[0059] (3) Encapsulation of polydopamine:
[0060] 10 mg DDMSNs-NH 2 -DOX in 1 mg mL -1 The target concentration was dispersed in Tris-HCl buffer (pH 9, 10 mM). Then add 20 mg DA to dissolve to 2 mg mL -1 soluti...
Embodiment 3
[0064] A method for preparing a GSH and PH dual-response drug delivery carrier for combined chemotherapy and photothermal therapy, comprising the following steps:
[0065] (1) Amino-modified degradable dendritic mesoporous silicon DDMSNs-NH 2 The preparation is with embodiment 1.
[0066] (2) Drug loading:
[0067] 50 mg DDMSNs-NH 2 Disperse in 50 mL 0.5 mg mL -1 DOX solution (water:PBS = 1:9), stirred at room temperature for 12 h in the dark. After drug loading, centrifuge at 20,000 rpm for 10 min, and collect the supernatant. Then wash with PBS until the supernatant is almost colorless. All the supernatants were collected, and the DOX content in the supernatant solution was measured at 488 nm with a UV-Vis spectrophotometer to calculate the drug loading.
[0068] (3) Encapsulation of polydopamine:
[0069] 10 mg DDMSNs-NH 2 -DOX in 1 mg mL -1 The target concentration was dispersed in Tris-HCl buffer (pH 10, 10 mM). Then add 40 mg DA to dissolve to 4 mg mL -1 solut...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More